Has anyone used obeticholic acid?

Obeticholic acid (Obeticholic acid), as a farnesoidX receptor agonist, has shown therapeutic potential in the treatment of primary cholangitis (PBC). As an emerging pharmacological target, farnesoid X receptors are being continuously explored for their various effects. One of the most significant effects in the treatment of primary cholangitis (PBC) is to reduce the concentration of bile acids in hepatocytes.

Currently, obeticholic acid has been approved for the treatment of adult patients with primary cholangitis who have failed to respond to conventional ursodeoxycholic acid (UDCA) or who are intolerant to UDCA. According to data from clinical trials, obeticholic acid can improve patients' biochemical markers such as alkaline phosphatase (ALP) and total bilirubin levels.

Studies conducted during the approval process for obeticholic acid, such as Study 747-302 and Study 747-401, defined strategies for its use in different severity settings. Study 747-302 was designed to evaluate the safety and efficacy of obeticholic acid in patients with early, moderately advanced and advanced PBC, specifically its impact on the primary composite clinical endpoint such as death or transplantation. Study 747-401, on the other hand, focused on PBC patients with moderate to severe liver impairment to determine the efficacy of obeticholic acid in these patients.

The recommended starting dose of obeticholic acid is 5 mg orally daily. However, for patients who have not seen adequate reductions in alkaline phosphatase or total bilirubin levels after six months, consideration may be given to increasing the dose to 10 mg daily in the hope of obtaining a better therapeutic response. After one year of treatment, if patients still do not see improvement in biochemical markers at the maximum effective dose (10 mg), doctors should comprehensively consider the clinical progression of primary cholangitis and the possible risks and benefits of continuing to use obeticholic acid.